|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.8301 - 0.8579|
|52-week range||0.8301 - 0.8579|
|Beta (5Y monthly)||1.21|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
A look at the shareholders of Adverum Biotechnologies, Inc. ( NASDAQ:ADVM ) can tell us which group is most powerful...
Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.
Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.